QURE Stock Crashes 32% in a Week: Here's What You Should Know

Core Viewpoint - Shares of uniQure N.V. (QURE) dropped 31.8% in a week due to a disappointing regulatory update regarding its gene therapy AMT-130 for Huntington's disease [1] Regulatory Update - uniQure received final meeting minutes from the FDA after a Type A meeting on January 30, 2026, indicating that the data from ongoing phase I/II studies are insufficient to support a marketing application [2] - The FDA strongly recommended a prospective, randomized, double-blind study with a sham surgery control to adequately evaluate AMT-130's efficacy [3] Company Strategy - Management believes that the existing data justifies continued engagement with the FDA despite not reaching alignment on a regulatory submission strategy [4] - uniQure plans to request a Type B meeting in Q2 2026 to explore study design options and clarify the regulatory pathway for AMT-130 [3] Clinical Data - High-dose AMT-130 reportedly slowed Huntington's disease progression by 75% after three years, with patients showing decreased levels of a key biomarker linked to neurodegeneration [6][5] - Prior to the recent regulatory feedback, uniQure had reported meeting key goals in the phase I/II study of AMT-130 [6][7] Other Developmental Programs - uniQure's clinical pipeline includes candidates for refractory mesial temporal lobe epilepsy, amyotrophic lateral sclerosis, and Fabry disease [9] - The company also markets a gene therapy for hemophilia B in partnership with CSL Behring under the brand name Hemgenix [10] Market Context - Over the past six months, QURE shares have declined by 38.9%, contrasting with the industry's growth of 19.6% [4]